Immunovant

Immunovant

IMVT· Manufacturing· Fiscal year ends in March

No proxy on file names the CEO of Immunovant.

Executives5

See all
  1. 1Peter Salzmann, M.D.FY2025
  2. 2Christopher Van TuylFY2025
  3. 3Melanie GloriaFY2025
  4. 4Michael Geffner, M.D.FY2025
  5. 5Eva Renee Barnett, M.B.A.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Immunovant paid its 5 named executives $30.3M in total in FY2025 (Mar).

Name
Peter Salzmann, M.D.Former Chief Executive OfficerNot disclosed
Christopher Van TuylChief Legal Officer and Corporate SecretaryNot disclosedNot disclosed
Melanie GloriaChief Operating OfficerNot disclosedNot disclosed
Michael Geffner, M.D.Chief Medical OfficerNot disclosedNot disclosed
Eva Renee Barnett, M.B.A.Former Chief Financial Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers13

See all

The FY2025 (Mar) proxy of Immunovant names 13 peer companies for pay. Among Immunovant and these peers, CEO pay was 5th highest of 7 and total shareholder return was 6th highest of 7.

5th highest of 7in Immunovant and its pay peers, FY2025 (Mar) by CEO pay:

$7.7M$19.2M

6th highest of 7in Immunovant and its pay peers, FY2025 (Mar) by total shareholder return:

$34$524

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • Jacob BauerDirector · 0 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive
  • Robert SusmanDirector · 0 yr on the boardIndependentAudit, Compensation—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AJul 9, 2025FY2025
Annual report10-KMay 29, 2025FY2025
Proxy statementDEF 14AJun 26, 2024FY2024
Annual report10-KMay 29, 2024FY2024
Proxy statementDEF 14AJun 26, 2023FY2023
Annual report10-KMay 22, 2023FY2023
For the press:Download CSVDownload PNGHow to use our data